Alopecia areata in London: the 2026 treatment landscape after JAK inhibitors
The alopecia areata conversation changed permanently the day JAK inhibitors were licensed. Here is what that means for London patients in 2026 — and what the treatment ladder still looks like below them.
Leila Nassar
Consultant Dermatologist · London teaching hospital
In short
- Alopecia areata (AA) is autoimmune — the immune system attacks anagen follicles. It is not stress, diet or hormone-driven.
- Around half of patchy AA regrows spontaneously within 12 months; more extensive disease (alopecia totalis/universalis) rarely does.
- Baricitinib (Olumiant) is NICE-approved on the NHS for severe adult AA — SALT score ≥50 — since 2023, and remains the biggest change in 30 years.
- Ritlecitinib (Litfulo) is licensed for age 12+ severe AA and available privately in London; NHS pathway is expanding.
- Intralesional steroid injections remain first-line for small patches — highly effective, in-clinic, £120–£250 per session.
- Topical minoxidil and topical/oral corticosteroids sit in the middle of the ladder — modest but useful.
- Contact immunotherapy (DPCP, SADBE) is a specialist-only NHS pathway for severe cases where JAKs are contraindicated.
- Children's AA is a separate treatment world — most systemic treatments are unlicensed under 12; specialist paediatric dermatology is essential.
- AA associates with thyroid disease, vitiligo, atopy — screening bloods are worth running once.
- Mental health support is not optional in extensive AA — Alopecia UK is a serious resource for London patients.
~2%
Lifetime UK risk
SALT ≥50
Baricitinib NHS access
~50% at 1 yr
Spontaneous regrowth (patchy)
£800–£1,600
Private JAK/mo
Alopecia areata has been the most therapeutically underserved of the common hair loss conditions for as long as I have been in dermatology. That changed in September 2023, when NICE approved baricitinib on the NHS for severe adult disease — the first meaningfully effective systemic treatment. Ritlecitinib followed in 2024. In 2026 we finally have a real medical conversation to offer patients, not just steroid injections and hope.
This guide walks through what we now do, in what order, for London patients — from the classic single patch on the back of the head to alopecia universalis. Written for patients, but with the treatment ladder your dermatologist is actually using.
What alopecia areata is
AA is an organ-specific autoimmune disease in which T cells attack the hair follicle bulb during the anagen (growth) phase. The follicle stops producing hair but does not die — which is why regrowth is possible even after decades of loss, unlike scarring alopecias.
Trichoscopy shows the classic features: yellow dots, black dots, exclamation-mark hairs and broken hairs at the patch edge. The patch is smooth, non-scarring, non-scaling — you can see the follicular openings clearly, and this is diagnostic.
The follicle in alopecia areata is asleep, not dead. Every treatment we have — old and new — is trying to wake it up by dampening the immune attack.
The severity map: SALT score
SALT (Severity of Alopecia Tool) scores scalp hair loss from 0 (no loss) to 100 (total loss). It matters because NHS access to JAK inhibitors is gated at SALT ≥50 (i.e. more than half of scalp hair lost). It also predicts spontaneous regrowth — small patches (SALT <25) regrow spontaneously in around half of cases; SALT >95 (alopecia universalis) almost never does without treatment.
- Patchy AA (SALT <25): intralesional steroids, topical minoxidil, watchful waiting — many resolve.
- Moderate AA (SALT 25–49): topical/systemic corticosteroids, contact immunotherapy, off-label JAKs privately.
- Severe AA (SALT ≥50): baricitinib (NHS, adults), ritlecitinib (NHS pathway expanding, ages 12+), contact immunotherapy.
- Alopecia totalis/universalis (SALT 95–100): JAK inhibitors first-line where accessible; realistic expectations are essential.
The current treatment ladder in London
Every dermatology unit's ladder looks slightly different, but the core sequence is fairly consistent in 2026:
- First line, patchy: intralesional triamcinolone 2.5–10 mg/ml, injected into the patch every 4–6 weeks. Highly effective for isolated patches.
- Adjunct: topical minoxidil 5%, twice daily — modest but useful during regrowth phase.
- Second line: potent topical corticosteroid (clobetasol) under occlusion, or short oral prednisolone course for rapidly progressive disease (relapse rate high on stopping).
- Third line, severe: baricitinib 4 mg daily (NHS, SALT ≥50, adult) — SALT reduction >30 in ~40% of patients at 36 weeks in trials. Ongoing treatment usually required.
- Third line, severe, age 12+: ritlecitinib 50 mg daily — similar efficacy, licensed for adolescents.
- Alternative: contact immunotherapy (DPCP) — deliberate low-grade allergic response weekly at a specialist NHS centre; effective in ~50%.
- Not on the ladder: PRP (limited AA evidence), transplant (contraindicated in active AA — grafts fail), 'natural' treatments (no evidence).
JAK inhibitors: what patients actually need to know
JAK inhibitors block the intracellular signalling that autoimmune T cells use to attack the follicle. They work — that is the news of the decade in AA. But they are not benign.
Baricitinib and ritlecitinib both carry EMA/MHRA warnings around infection risk (herpes zoster, TB reactivation), thromboembolic events, and modest cardiovascular signals. Screening bloods, TB status, vaccination review and shared decision-making are essential before starting. Monitoring bloods run 3-monthly.
Efficacy typically appears at 3–6 months; peak at 9–12 months. Stopping tends to be followed by relapse within 6 months, so most patients are on treatment long-term. NHS access is gated tightly; private access in London runs £800–£1,600/month depending on dose and clinic markup.
Children and adolescents
Paediatric AA is common — around 20% of cases start under 16. The treatment landscape is more conservative: intralesional steroids only in older children who can tolerate them, topical treatments as mainstay, and specialist supportive care around school, self-image and mental health.
Ritlecitinib is now licensed from age 12 and this has meaningfully changed the adolescent conversation. Under 12, systemic treatment remains largely off-label and requires paediatric dermatology input. London options: Great Ormond Street, St Thomas' and Guy's, and the Royal Free all run paediatric hair clinics.
Living with alopecia areata
Even the best medical treatment is a slow, uncertain conversation. Real 2026 patient care includes: wig fitting (NHS entitlement for extensive loss, or Alopecia UK's grant scheme), cosmetic camouflage (dermatography, eyebrow microblading, false eyelashes for AU), and mental health support — anxiety and depression are meaningfully higher in AA, and support groups reduce that.
Alopecia UK, based in the UK, runs London meetups and has been a serious resource for two decades. Every London dermatology clinic should be pointing you at them.
Treating the follicle is only half of alopecia areata. Treating the person is the other half — and it is not soft to say so.
Take this with you
What to ask a London clinic
Copy these into your notes app before any consult. Any specialist worth your money will welcome them.
- 1What is my SALT score today, and how does that affect my treatment options?
- 2Am I NHS-eligible for baricitinib or ritlecitinib, or is private the only route?
- 3What is the realistic probability my patches regrow without treatment in the next 12 months?
- 4What screening bloods and vaccination checks do you need before starting a JAK inhibitor?
- 5What is your plan if I respond to a JAK and then need to stop?
- 6Which support organisation would you recommend for someone in my situation in London?
Frequently asked
Common questions
What causes alopecia areata?+
It is an autoimmune condition — T cells attack the hair follicle. There is a strong genetic component (family history in ~20% of cases). It is not caused by stress, diet, shampoos or hormones, although stress can occasionally act as a trigger event.
Will my alopecia areata grow back?+
For small patches (SALT <25), around half regrow spontaneously within 12 months. For extensive disease (alopecia totalis/universalis), spontaneous regrowth is rare and treatment is usually needed.
Is alopecia areata contagious?+
No. It is autoimmune, not infectious.
Can alopecia areata be cured?+
There is no cure yet, but JAK inhibitors have transformed treatment. Many patients achieve full regrowth on JAKs, though most need ongoing treatment to maintain it.
How much does baricitinib cost privately in London?+
£800–£1,400 per month including prescription and clinic monitoring, depending on clinic. NHS access requires SALT ≥50 and specialist dermatology referral.
Is ritlecitinib available in London?+
Yes. Ritlecitinib (Litfulo) is licensed for severe AA aged 12+ and available privately in London. NHS access is expanding. Discuss with a consultant dermatologist.
Do steroid injections hurt?+
They sting briefly. Modern practice uses very fine needles and a small volume per injection point. Most patients tolerate 20–40 injection points per session comfortably.
Can PRP help alopecia areata?+
Evidence in AA is limited and inconsistent. It is not first-line and NHS does not fund it for AA. Some London private clinics offer it — expectations should be low compared to intralesional steroids or JAKs.
Can I get a hair transplant for alopecia areata?+
Transplants are contraindicated in active AA — the immune attack destroys grafts. In long-stable, localised loss with no activity for years, individual case discussion is possible with a hair restoration surgeon.
Where in London can I get NHS treatment for alopecia areata?+
Any dermatology department. Larger units with hair specialty clinics include St Thomas', Guy's, King's, Royal Free, and St John's Institute of Dermatology. GP referral is required.
What is the difference between alopecia areata, totalis and universalis?+
Areata = patchy scalp loss. Totalis = complete scalp loss. Universalis = complete loss of scalp and body hair. Same disease, different severity.
Do children with alopecia areata grow out of it?+
Prognosis varies — some children have single episodes that resolve, others progress. Early onset and family history are prognostic markers for a more chronic course. Specialist paediatric dermatology input is important.
Sources & further reading
References
- [1]NICE TA926: Baricitinib for treating severe alopecia areata, 2023
- [2]King BA et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. NEJM, 2022
- [3]King BA et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata. Lancet, 2023
- [4]Alopecia UK — support and information for patients
- [5]British Association of Dermatologists — clinical guidelines on alopecia areata
Reviewed by
Leila Nassar
Consultant Dermatologist · London teaching hospital
Leila Nassar MRCP(Derm) is a consultant dermatologist with a subspecialty interest in hair and scalp disease at a large London teaching hospital. She runs a weekly cicatricial alopecia clinic and lectures nationally on medical management of hair loss.
Keep reading
Related, trichologist-reviewed
Scalp
Frontal fibrosing alopecia in London — the rising cause of hairline loss in women
Frontal fibrosing alopecia now accounts for more than 1 in 5 hairline-loss consultations in London women over 50. Speed of diagnosis decides speed of arrest.
Read
Hair loss
Traction alopecia in London: protective styles and the science of regrowth
Traction alopecia is preventable, reversible if caught early, and one of the most common causes of frontal hair loss in London's Black community.
Read
Scalp
Trichotillomania in London — the hair-pulling disorder that isn't a habit
Trichotillomania is a neurobiological condition, not a habit or a phase. It responds to specific therapy — and London has the specialists to deliver it.
Read
Treatments
Medical wig fitting in London — NHS, private, and what to expect
A well-fitted medical wig is invisible, comfortable, and life-restoring. Here is how to get one in London — free and paid.
Read